Newborn screening and related policy against Phenylketonuria in China
スポンサーリンク
概要
- 論文の詳細を見る
Phenylketonuria (PKU) is a treatable and preventable inherited metabolic disease. The overall incidence of PKU in China is 1/11,144. Newborn screening is an effective method of controlling PKU. In1981, the Chinese Government initiated a newborn screening program and the number of newborns screened for PKU in China has risen each year. This review describes the current status of laws and regulations related to newborn screening for PKU in China and it identifies how China's newborn screening program has improved as a result of these laws and regulations. Specific measures and regulations, such as those implemented by government, follow-up services, and government coverage of expenses, have been implemented in different areas where they have yielded good results. These measures and regulations may serve as a reference for other areas of China. However, measures and regulations regarding newborn screening in China still face challenges. Prenatal health examinations and national financial support are expected to play a more significant role in
- 特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会の論文
特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会 | 論文
- Traditional Chinese medicine and related active compounds: A review of their role on hepatitis B virus infection
- The etiologies of new cases of cerebral venous sinus thrombosis reported in the past year
- The supercritical CO2 extract from the skin of Bufo bufo gargarizans Cantor blocks hepatitis B virus antigen secretion in HepG2.2.15 cells
- HDAC6: Physiological function and its selective inhibitors for cancer treatment
- High prevalence of HIV-associated neurocognitive disorder in HIV-infected patients with a baseline CD4 count ≤ 350 cells/μL in Shanghai, China